PHARMACOVIGILANCE PLAN FOR TANZANIA PREPARED BY EMMA & MARY 10 TH SEPTEMBER 2004.

Slides:



Advertisements
Similar presentations
YOUR ROLE IN REALISING THE AUSTRALIAN CHARTER OF HEALTHCARE RIGHTS A TRAINING GUIDE FOR HEALTHCARE PROFESSIONALS.
Advertisements

Sevene E, Mariano A, Mola D Faculty of Medicine / Ministry of Health Pretoria, September 2004 PHARMACOVIGILANCE SYSTEM - MOZAMBIQUE INTRODUCING PV INTO.
Canadian Disclosure Guidelines. Disclosure - Background Process began: May 2006 Background research and document prepared First working draft created.
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
Abstract The Knowledge, Perceptions, and Practice of Pharmacovigilance among Community Pharmacists in Lagos State, Southwest Nigeria Oreagba, Ibrahim Adekunle.
COUNTRY ACTION PLAN for INTRODUCING AND IMPLEMENTING A PHARMACOVIGILANCE PROGRAMME IN KENYA Dorine Kagai and Wilfred Oguta Pretoria,2004.
Nigeria Dr Uzono Levi and Pharm Adegboyega Adewumi 10 th September 2004 Discussions on Country Plans Presented at the WHO Training Course on Introduction.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
ROLE OF NURSES IN CLINICAL RESEARCH IN MALAWI OWEN DAIRE BSCN MPH RNM.
Safety and Vigilance (SAV)
Zambia Pharmacovigilance Action Plan National Plan Revision Proposal Dr Albert Mwango Mrs Bernice MwaleSeptember 2004.
Progress on implementation of Pharmacovigilance in the NATIONAL ARV PROGRAMME November 2009 Dr Mwango A National ARV Programme Coordinator, Ministry of.
Basic Pharmacovigilance Training
Community Planning Training 1-1. Community Plan Implementation Training 1- Community Planning Training 1-3.
CARE Capability Building Mentoring Program Guide for Supervisors of Mentees.
Isah, Ambrose Ohumagho (1); Pal, Shanthi (2); Olsson, Sten (3)
Pharmacovigilance in Kenya Dr. Dorine Kagai (NASCOP) Mr. George Muthuri (PPB) Ministry of Medical Services 23 nd November, 2009 ARV PV TRAINING TZ.
Pharmacovigilance Programme of India
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Topic 6 Understanding and managing clinical risk.
Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS I Ralph Edwards.
How to use the EFQM Excellence Model to empower patients and staff create a latex- safe environment Karen Cunningham Health & Safety Manager Musgrave Park.
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
Sten Olsson WHO Programme Expert Uppsala Monitoring Centre Sweden
Pharmacy and Poisons Board Pharmacy and Poisons Board, Kenya Role of Regulation in Optimizing Medicine use KNH/UON Pharmacy Symposium Optimizing Medicine.
1 Thank you for visiting our site and welcome to the “Introduction to ISO 22000” Presentation that you requested. For more information.
Prime Responsibility for Radiation Safety
Lucile de Comarmond Chief Pharmacist Workshop on Impact of TRIPS/IP on Access to Medicine September 2014.
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
CRICOS Number 00213J Australian Health Protection Committee Disaster Health Strategic Leadership Program Prof. Gerry FitzGerald.
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
Programme Performance Criteria. Regulatory Authority Objectives To identify criteria against which the status of each element of the regulatory programme.
Livesy Abokyi Kintampo Health Research Centre 9 th INDEPTH AGM th October,2009 Pune, INDIA.
Training course on the Pharmacovigilance of antiretroviral medicines 23 – 28 November 2009 Rationale, Objectives and Expected Outcomes.
“USAPI-PHARMACY ASSOCIATION - RESPONSE TO NCD ROADMAP” Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa 51 st 1-18 nov 2011 Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa.
Understanding Monitoring & Indicators. What is Monitoring?  A continuing function that uses systematic collection of data on specified indicators to.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.
Minimum requirements for Pharmacovigilance in countries.
Single Competency Framework for Prescribers National Prescribing Centre (2012)
Feasibility of establishing PVC in the Ugandan health system By Juliet & Martin September 2004.
Core Topic 11 Documentation, record keeping and reporting.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
1 QUALITY MANAGEMENT SYSTEM PRESENTATION TO BOTSWANA DRUG ADVISORY BOARD MEMBERS 13 th – 17 th AUGUST 2007.
VICH General Principles and current update of VICH Outreach Forum activity 1.
VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
CHILDREN OF PRISONERS PARTNERSHIP What is the Children of Prisoners (CP) Partnership? The CP Partnership is a funding project between PFI and selected.
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Program Performance Criteria.
1 Pharmacovigilance & the New National Adverse Drug Reaction (ADR) Reporting System Michael Bonett, Quality Assessor Post-Licensing Directorate Medicines.
BC SUPPORT Unit: Overview and update
Detection & monitoring of ADR
Overview of the EAC Pharmacovigilance and Post-Marketing Surveillance Systems 1ST International High Level Multi-Stakeholder Conference Nairobi, 2-4.
Risk Communication in Medicines
8. Causality assessment:
11 viii. Develop capacity for signal detection and causality assessment Multi-partner training package on active TB drug safety monitoring and management.
11 ii. Develop a plan for aDSM
Pharmacovigilance in clinical trials
Establishing the Infrastructure for Radiation Safety Preparatory Actions and Initial Regulatory Activities.
9. Introduction to signal detection
Quality Assurance and Safety of Medicines
Developing pharmacovigilance: new challenges and opportunities Mary Couper and Shanthi Pal Quality Assurance and Safety of Medicines.
Pharmacovigilance in Uganda
Helen Lee, European Commission
RECORDS AND INFORMATION
Pharmacovigilance What? (2.6) Ensure ADR monitoring (Spontaneous reporting/Cohort studies) Who? Healthcare workers How? WHO International Drug Monitoring.
Medicines Safety Mary R. Couper
11 iii. Define management and supervision roles and responsibilities
Presentation transcript:

PHARMACOVIGILANCE PLAN FOR TANZANIA PREPARED BY EMMA & MARY 10 TH SEPTEMBER 2004

PLAN Justification for monitoring of drugs. To make sure that drugs for the public health use are of acceptable quality, safety and efficacious. All drugs circulating in the market are supposed to be monitored. Reports to be investigated Every report need a follow up because they play part and parcel of safety monitoring of drugs.

Cont…. The following reports need to be investigated: clusters, Unexpected, Unusual and non compliance reports. Investigation should be on: Group of individuals affected. Quality of the products. Outcome of the treatment. Frequency of occurrence of the ADR including causal relationship.

Cont…. Roles and responsibilities in monitoring. Tanzania Food and Drugs Authority The roles of the authority is to monitor safety of all drugs in the country. The system of collecting information (reports) is in place. From sentinel centres and from healthcare providers to TFDA.

Cont…… The plan is to encourage patients to report to TFDA and zonal offices (to be established). Manufacturers and product registrants have the responsibility of monitoring their products and send reports to TFDA. Feedback reports from TFDA will be sent to all including the media depending on circumstances. In addition… All health workers have the responsibility of monitoring proper management of drugs at their capacity (reporting of suspected quality problems and drug administration).

cont… Monitoring Processes Spontaneous monitoring: § Is in place for all registered pharmaceuticals products and those registered for study. Cohort studies: § Will be a priority especially with ART Programme. Registries: § If record keeping system is improved, monitoring using registries will be incorporated.

Reporting of events or reactions As soon as the patients are using the drugs the reporting on adverse reactions will continue to be encouraged. With ARVs and drugs which are on studies the reporting on adverse events and adverse reactions is encouraged.

What should be the timelines for submitting; Initial reports, Three days after filling of the forms, these should be posted. Investigations reports, As soon as possible when the investigation is still on progress. Aggregate reports? Bi annual.

6.How do you manage non-serious ADRs? Both serious and non serious ADRs are encouraged to be reported. 7. What are the resources available? Based on resources, size of country and nature of public health structures There is drug regulatory authority. Functional Pharmacovigilance centre. Organized health systems in place. Government commitment on Public health programs.

8. What are the critical success factors to achieve the system and its objectives? Inadequate human resource, five more people need to be recruited. Financial resource is not adequate to perform all the pv activities. Infrastructure and equipment need to be improved More support is needed from the upper to the lower level. Technical support to conduct more activities eg research.

TRAINING STRATEGIES Training of TOTs (Regional Health Management Teams). Facilitators from the PV centre and TFDA. Training Curriculum preparation. Preparation of Training materials Meeting of the facilitators and experts to agree on the training materials and curriculum.

Curriculum Contents: Introduction: The definition of pharmacovigilance Importance of pharmacovigilance in Public health. Magnitude of the adverse effects of drugs The importance of monitoring adverse drugs reactions.

Contents cont… The pharmacological basis of adverse drug reactions and classification of ADR based on etiology. How to recognize ADR Principle of efficient reporting. When and what to report. How to report. Ways of improving ADR monitoring and reporting Communication on feedback of the reports.

Curriculum cont… Each session will consist of thirty participants with four facilitators. Training methods Participatory, Role plays and Group discussion Number of hours for the training: The training session is expected to take 3 days or a total of 24 hours.

Training Schedule Training will be conducted in the six zones which will consist of four regions each with seven participants. (TOT). These training will be covered within three months. Sensitization of the trained professionals will be done on quarterly basis. During annual professionals meetings there will be a session to remind health workers the importance of ADR reporting.

Training of TOTs The objective of Training in general is to ensure that health workers are well educated on the importance of safety monitoring of drugs as well as to increase the reporting of adverse drug reactions. Trained TOT will help in training other health workers in their respective regions.

To the community….. The use of media will be of emphasis: Different communication channels will be used, leaflets, posters, radios, magazines etc. To the retail pharmacies, the pharmacists will be encouraged to sensitize their customers on reporting of adverse reactions they encounter. The objective of sensitizing communities is to raise their awareness on the harmful effects drugs can cause.